Royalties earned percentage of revenue.

No definition available.

Name:	rvmd_RoyaltiesEarnedPercentageOfRevenue
Namespace Prefix:	rvmd_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty payments termination description.

+ References

No definition available.

+ Details

Name:	rvmd_RoyaltyPaymentsTerminationDescription
Namespace Prefix:	rvmd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty rate projections description.

+ References

No definition available.

+ Details

Name:	rvmd_RoyaltyRateProjectionsDescription
Namespace Prefix:	rvmd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront cash payment received.

+ References

No definition available.

+ Details

Name:	rvmd_UpfrontCashPaymentReceived
Namespace Prefix:	rvmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details

Name:	us-gaap_PaymentsOfDebtIssuanceCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_LongtermDebtTypeAxis=rvmd_TrancheTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongtermDebtTypeAxis=rvmd_TrancheThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rvmd_RoyaltyPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rvmd_RoyaltyPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=rvmd_TrancheTwoFundingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=rvmd_TierOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=rvmd_TierTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=rvmd_TierThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=rvmd_TierFourMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongtermDebtTypeAxis=rvmd_TrancheFourMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongtermDebtTypeAxis=rvmd_TrancheFiveMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Liability Related to the Sale of Future Royalties - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		6 Months Ended
	May 31, 2026	Jun. 30, 2025	Jun. 30, 2026
Deferred Revenue Arrangement [Line Items]
Upfront cash payment		$ 250,000
Aggregate tranches totaling amount		750,000
Debt issuance costs		10,800	$ 5,000
Tranche Two
Deferred Revenue Arrangement [Line Items]
Upfront cash payment		250,000
Aggregate tranches totaling amount		250,000
Tranche Three
Deferred Revenue Arrangement [Line Items]
Aggregate tranches totaling amount		250,000
Royalty Purchase Agreement \| Royalty Pharma
Deferred Revenue Arrangement [Line Items]
Upfront cash payment		250,000
Royalty payments termination description			The Company’s obligations under the Royalty Purchase Agreement will terminate upon the fifteenth anniversary of the first commercial sale of an RMC-6236 Product in the United States (or in the European Union for ex-U.S. sales).
Aggregate tranches totaling amount		$ 750,000
Royalty rate projections description		the Royalty Purchase Agreement provides for an upward adjustment to the Royalty Payment rates in the years from 2030 to 2041 in the event that annual net sales in the immediate prior year are below an agreed-upon threshold. The upward adjustment to the Royalty Payment rates applies only to the $0 to $2 billion annual net sales tier, and the adjusted total Royalty Payment rate for this tier remains in the single digits. Any upward adjustment will revert back to the original Royalty Payment rates in the event that annual net sales are above a different agreed-upon threshold.
Royalty Purchase Agreement \| Royalty Pharma \| Tranche 2 Funding
Deferred Revenue Arrangement [Line Items]
Upfront cash payment	$ 250,000
Royalty Purchase Agreement \| Royalty Pharma \| Tier One
Deferred Revenue Arrangement [Line Items]
Percentage of royalty payments received	4.55%
Royalty Purchase Agreement \| Royalty Pharma \| Tier Two
Deferred Revenue Arrangement [Line Items]
Percentage of royalty payments received	2.50%
Royalty Purchase Agreement \| Royalty Pharma \| Tier Three
Deferred Revenue Arrangement [Line Items]
Percentage of royalty payments received	1.00%
Royalty Purchase Agreement \| Royalty Pharma \| Tier Four
Deferred Revenue Arrangement [Line Items]
Percentage of royalty payments received	0.00%
Royalty Purchase Agreement \| Royalty Pharma \| Maximum \| Tier One
Deferred Revenue Arrangement [Line Items]
Net Sales	$ 2,000,000	$ 2,000,000
Royalty Purchase Agreement \| Royalty Pharma \| Maximum \| Tier Two
Deferred Revenue Arrangement [Line Items]
Net Sales	4,000,000
Royalty Purchase Agreement \| Royalty Pharma \| Maximum \| Tier Three
Deferred Revenue Arrangement [Line Items]
Net Sales	8,000,000
Royalty Purchase Agreement \| Royalty Pharma \| Minimum \| Tier One
Deferred Revenue Arrangement [Line Items]
Net Sales		$ 0
Royalty Purchase Agreement \| Royalty Pharma \| Minimum \| Tier Two
Deferred Revenue Arrangement [Line Items]
Net Sales	2,000,000
Royalty Purchase Agreement \| Royalty Pharma \| Minimum \| Tier Three
Deferred Revenue Arrangement [Line Items]
Net Sales	4,000,000
Royalty Purchase Agreement \| Royalty Pharma \| Minimum \| Tier Four
Deferred Revenue Arrangement [Line Items]
Net Sales	$ 8,000,000
Royalty Purchase Agreement \| Royalty Pharma \| Tranche Two
Deferred Revenue Arrangement [Line Items]
Percentage of royalty payments received		7.80%
Royalty Purchase Agreement \| Royalty Pharma \| Tranche Two \| Maximum
Deferred Revenue Arrangement [Line Items]
Net Sales		$ 2,000,000
Royalty Purchase Agreement \| Royalty Pharma \| Tranche Three
Deferred Revenue Arrangement [Line Items]
Percentage of royalty payments received		4.55%
Royalty Purchase Agreement \| Royalty Pharma \| Tranche Three \| Maximum
Deferred Revenue Arrangement [Line Items]
Aggregate tranches totaling amount		$ 250,000
Net Sales		4,000,000
Royalty Purchase Agreement \| Royalty Pharma \| Tranche Three \| Minimum
Deferred Revenue Arrangement [Line Items]
Net Sales		2,000,000
Royalty Purchase Agreement \| Royalty Pharma \| Tranche Four
Deferred Revenue Arrangement [Line Items]
Aggregate tranches totaling amount		$ 250,000
Percentage of royalty payments received		2.40%
Royalty Purchase Agreement \| Royalty Pharma \| Tranche Four \| Maximum
Deferred Revenue Arrangement [Line Items]
Net Sales		$ 8,000,000
Royalty Purchase Agreement \| Royalty Pharma \| Tranche Four \| Minimum
Deferred Revenue Arrangement [Line Items]
Net Sales		4,000,000
Royalty Purchase Agreement \| Royalty Pharma \| Tranche Five
Deferred Revenue Arrangement [Line Items]
Aggregate tranches totaling amount		$ 250,000
Percentage of royalty payments received		0.00%
Royalty Purchase Agreement \| Royalty Pharma \| Tranche Five \| Maximum
Deferred Revenue Arrangement [Line Items]
Aggregate tranches totaling amount		$ 100,000
Royalty Purchase Agreement \| Royalty Pharma \| Tranche Five \| Minimum
Deferred Revenue Arrangement [Line Items]
Net Sales		$ 8,000,000